Why Galapagos Stock Is Crashing Today
The FDA dealt the biotech and its big partner a huge setback.
Galapagos
GLPG
GLPG
$124.82
-$2.37
-1.9%
Price as of December 2, 2020, 9:00 p.m. EST
View Interactive GLPG Charts
GALAPAGOS NV SPON ADR REPR 1 ORD SHS
Interactive Chart
News & Analysis: Galapagos
Galapagos NV (GLPG) Q2 2020 Earnings Call Transcript
GLPG earnings call for the period ending June 30, 2020.
3 Biotech Stocks With Big Incoming Catalysts
Binary events could send shares of these stocks screaming higher, or lower, soon.
Better Buy: Vertex Pharmaceuticals vs. Galapagos
Is an industry leader in treating cystic fibrosis or a company with a potential miracle drug the better buy for investors?
Galapagos and Gilead Sciences Post Successful Yet Disappointing Filgotinib Results
In a phase 2b/3 study in ulcerative colitis, the drug candidate met its goals, but with results that didn't appear better than those of a potential competitor.
Galapagos NV (GLPG) Q1 2020 Earnings Call Transcript
GLPG earnings call for the period ending March 31, 2020.
Is Galapagos Stock a Buy?
Investors may want to own this biotech before its lead drug gets approved.
Is It Too Late to Buy High-Flying Galapagos?
Immunology drug filgotinib appears to have great prospects. But are those prospects already baked into Galapagos' share price?
Galapagos NV (GLPG) Q4 2019 Earnings Call Transcript
GLPG earnings call for the period ending December 31, 2019.
Better Buy: Vertex Pharmaceuticals vs. Galapagos
One of these biotechs dominates the treatment of cystic fibrosis. The other doesn't have a single FDA-approved drug -- yet.
